Long-Acting Drug Market Projected to Hit US$ 13.3 Billion by 2033

The surge in demand is primarily fueled by the global prevalence of chronic diseases, where traditional daily regimens often fail due to patient non-adherence. By reducing the frequency of administration, long-acting injectables and polymer-based depots ensure consistent therapeutic levels, which are critical for managing complex conditions such as HIV, schizophrenia, and cardiovascular disorders.

Technological innovation remains the primary catalyst for this transition. Microsphere-based systems currently lead the delivery segment, offering controlled release profiles that improve both stability and patient outcomes. Beyond injectables, the industry is increasingly focused on oral long-acting biologics. A prime example is Eli Lilly’s progress with orforglipron, an oral GLP-1 receptor agonist that aims to simplify diabetes and obesity management by removing the food and water intake restrictions common to existing therapies.

North America continues to dominate the landscape, holding a 41.2% market share bolstered by heavy investment in pharmaceutical research and robust healthcare infrastructure. Meanwhile, the Asia Pacific region is emerging as the fastest-growing hub, driven by broader healthcare access and government initiatives supporting drug delivery innovation. As manufacturers refine these delivery technologies, competition is expected to intensify across the oncology and metabolic health sectors.